Publications
Detailed Information
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, D-W | - |
dc.contributor.author | Kim, S-Y | - |
dc.contributor.author | Kim, H-K | - |
dc.contributor.author | Kim, S-W | - |
dc.contributor.author | Shin, S W | - |
dc.contributor.author | Kim, J S | - |
dc.contributor.author | Park, K | - |
dc.contributor.author | Lee, M Y | - |
dc.contributor.author | Heo, D S | - |
dc.date.accessioned | 2010-01-07T02:09:33Z | - |
dc.date.available | 2010-01-07T02:09:33Z | - |
dc.date.issued | 2007-09-06 | - |
dc.identifier.citation | Ann Oncol. 2007 Dec;18(12):2009-14. Epub 2007 Sep 4. | en |
dc.identifier.issn | 1569-8041 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17785767 | - |
dc.identifier.uri | https://hdl.handle.net/10371/27833 | - |
dc.description.abstract | BACKGROUND: Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC received Genexol-PM 230 mg/m(2) and cisplatin 60 mg/m(2) on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m(2) was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle. RESULTS: Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively). CONCLUSION: Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity. | en |
dc.language.iso | en | en |
dc.publisher | Oxford University Press | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/administration & | en |
dc.subject | dosage/*therapeutic use | en |
dc.subject | Carcinoma, Non-Small-Cell Lung/*drug therapy | en |
dc.subject | Cisplatin/administration & dosage | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms/*drug therapy | en |
dc.subject | Male | en |
dc.subject | Micelles | en |
dc.subject | Middle Aged | en |
dc.subject | Paclitaxel/administration & dosage | en |
dc.subject | Polymers | en |
dc.subject | Treatment Outcome | en |
dc.title | Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer | en |
dc.type | Article | en |
dc.identifier.doi | 10.1093/annonc/mdm374 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.